ALK's tree allergy SLIT meets in Phase III for birch pollen allergy

In September, ALK-Abello A/S (CSE:ALK-B) reported data from a Phase III trial in 634 patients ages 12-65 with birch pollen allergic rhinitis and/or conjunctivitis showing that tree allergy sublingual immunotherapy (SLIT) met the primary endpoint of reducing daily total combined score vs. placebo (p<0.0001). Specifically, the tree allergy SLIT tablets reduced the total combined score -- defined as the sum of the allergic symptom score and the use of symptom-relieving medication during the birch pollen season -- by 39.6% vs. placebo. The product was well tolerated.

Secondary endpoints in the double-blind, European trial include allergic rhinoconjunctivitis symptom and daily medication scores, number of mild and severe days, Rhinoconjunctivitis Quality of Life Questionnaire score, rhinoconjunctivitis symptom visual analog score (VAS), patient-rated global evaluation and safety...